2009
Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines
LAINE L, CONNORS L, GRIFFIN MR, CURTIS SP, KAUR A, CANNON CP. Prescription rates of protective co‐therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Alimentary Pharmacology & Therapeutics 2009, 30: 767-774. PMID: 19594486, DOI: 10.1111/j.1365-2036.2009.04090.x.Peer-Reviewed Original Research
2004
Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis
Ofman JJ, Badamgarav E, Henning JM, Knight K, Laine L. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. The American Journal Of Medicine 2004, 116: 835-842. PMID: 15178499, DOI: 10.1016/j.amjmed.2004.02.028.Peer-Reviewed Original ResearchConceptsCOX-2 inhibitorsCardiac eventsHealth care costsGastrointestinal bleedingTraditional NSAIDsHigh riskGreater total health care costsNonsteroidal anti-inflammatory drug therapyCare costsAnti-inflammatory drug therapyCOX-2 inhibitor therapyTotal health care costsCyclooxygenase-2 selective inhibitorNonsteroidal anti-inflammatory drugsCardiac risk profileProton pump inhibitorsAnti-inflammatory drugsLogistic regression analysisNSAID therapyNSAID usersGastrointestinal riskInhibitor useNonselective NSAIDsInhibitor therapyCardiac riskProton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? Gastroenterological Disorders 2004, 4 Suppl 4: s33-41. PMID: 15580145.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsUpper GI symptomsNonselective nonsteroidal anti-inflammatory drugsLow-dose aspirinAnti-inflammatory drugsGI symptomsGI complicationsGI riskSide effectsDevelopment of NSAIDDaily proton pump inhibitor therapyHistamine-2 receptor antagonistsNSAID-induced gastric ulcersProton pump inhibitor therapyNSAID-induced ulcersGI side effectsUpper GI bleedingAnti-pyretic effectsGastrointestinal toxicityGI bleedingNSAID usersUlcer complicationsCardiovascular prophylaxisInhibitor therapyStandard doses
2001
Stratilying the risk of clinical upper Gl events in NSAID users: Results from a double-blind outcomes study
Laine L, Hawkey C, Bombardier C, Shapiro D, Reicin A. Stratilying the risk of clinical upper Gl events in NSAID users: Results from a double-blind outcomes study. Gastroenterology 2001, 120: a105. DOI: 10.1016/s0016-5085(08)80513-6.Peer-Reviewed Original ResearchNSAID usersOutcome studiesStratilying the risk of clinical upper Gl events in NSAID users: Results from a double-blind outcomes study
LAINE L, HAWKEY C, BOMBARDIER C, SHAPIRO D, REICIN A. Stratilying the risk of clinical upper Gl events in NSAID users: Results from a double-blind outcomes study. Gastroenterology 2001, 120: a105-a105. DOI: 10.1016/s0016-5085(01)80513-8.Peer-Reviewed Original ResearchNSAID usersOutcome studiesApproaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120: 594-606. PMID: 11179238, DOI: 10.1053/gast.2001.21907.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsGI eventsGI diseasePrevention of NSAIDAnti-inflammatory drug useClinical upper GI eventsHistory of ulcerUpper GI eventsHalf of patientsHigh-risk patientsAnti-inflammatory drugsGastrointestinal eventsNSAID doseGastroduodenal injuryNSAID usersClinical featuresGastric erosionsSteroid useCommon causeDrug usePatientsUlcersDiseaseRiskUnited States today
1993
HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA
Laine L. HELICOBACTER PYLORI, GASTRIC ULCER, AND AGENTS NOXIOUS TO THE GASTRIC MUCOSA. Gastroenterology Clinics Of North America 1993, 22: 117-125. PMID: 8449561, DOI: 10.1016/s0889-8553(21)00267-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsH. pylori prevalenceGastric ulcerHistologic gastritisH. pyloriGastric injuryPylori prevalenceDuodenal ulcerGastric mucosaNoxious agentsInflammatory cell infiltrateH. pylori infectionNSAID usersCell infiltratePylori infectionDuodenal contentsNSAIDsUlcersGross injuryGastritisPatientsHelicobacter pyloriPyloriInjuryMucosaPrevalence